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With the development of nanotechnology, special attention has been given to the nanomaterial application in
tumor treatment. Here, a modified desolvation-cross-linking method was successfully applied to fabricate
gemcitabine-loaded albumin nanospheres (GEM-ANPs), with 110 and 406 nm of mean diameter, respectively. The
aim of this study was to assess the drug distribution, side effects, and antitumor activity of GEM-ANPs in vivo. The
metabolic viability and flow cytometry analysis revealed that both GEM-ANPs, especially 406-nm GEM-ANPs, could
effectively inhibit the metabolism and proliferation and promote the apoptosis of human pancreatic carcinoma
(PANC-1) in vitro. Intravenous injection of 406-nm GEM-ANPs exhibited a significant increase of gemcitabine in the
pancreas, liver, and spleen of Sprague–Dawley rats (p < 0.05). Moreover, no signs of toxic side effects analyzed by
blood parameter changes were observed after 3 weeks of administration although a high dose (200 mg/kg) of
GEM-ANPs were used. Additionally, in PANC-1-induced tumor mice, intravenous injection of 406-nm GEM-ANPs also
could effectively reduce the tumor volume by comparison with free gemcitabine. With these findings, albumin
nanosphere-loading approach might be efficacious to improve the antitumor activity of gemcitabine, and the
efficacy is associated with the size of GEM-ANPs.
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Chemotherapy is an important method of adjuvant ther-
apy for pancreatic cancer. Gemcitabine, 20,20-difluoro-20-
deoxycytidine, remains the standard of use and has more
significant clinical benefit than fluorouracil (5-FU)
(clinical benefit response, 23.8% of gemcitabine treated
patients vs. 4.8% of 5-FU-treated patients, p = 0.0022)
[1,2]. However, gemcitabine has a short half-life in vivo
and will be rapidly and extensively decomposed to
inactive products in the blood, liver, kidney, and other
tissues by cytidine deaminase [3]. For example, at the
standard dose of 1,000 mg/m2, a patient’s plasma
gemcitabine concentration dropped to only 0.4 μg/mL in
1 h after intravenous infusion, considerably below the 5-* Correspondence: galleyking@hotmail.com
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in any medium, provided the original work is pμg/mL optimal plasma concentration for cancer cell in-
hibition [4]. Thus, a larger dose is necessary, while it
poses a greater risk of side effects. It has been docu-
mented that change in the formulation of gemcitabine
might be a way to reduce side effects and improve the
drug biopharmaceutical features [5]. For example,
Paolino et al. found that gemcitabine-loaded PEGylated
unilamellar liposomes could promote the concentration
of the drug inside the tumor and increase the plasmatic
half-life of gemcitabine [3]. Moreover, this formulation
did not display any blood toxicity.
Of the various formulations available, nanospheres
with a mean diameter of 10 to 1,000 nm are widely used
as carriers in drug delivery systems in clinical applica-
tions [6,7]. They have some potential chemotherapeutic
advantages for the treatment of tumors, including pan-
creatic cancer. Firstly, they can be biodegradable after
intravenous injection. Secondly, owing to enhanced per-
meability and retention (EPR) effects, nanospheresen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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them in the target organ so that their toxicity would be
enhanced in tumor tissues while reduced in normal tis-
sues [8-10]. Furthermore, tumor cells, Kupffer cells, and
mononuclear phagocyte system have higher phagocytotic
rates for uptaking nanoparticles than other tissue cells.
Therefore, the nanospheres loaded with drugs could be
targeted to tumor, the liver, or spleen [11].
As the most abundant protein in the body, albumin is
playing an increasing role as a drug carrier in the clinical
setting, without hemolytic and immunogenic problems
[12-14]. Previously, our research group designed a
modified desolvation-cross-linking method to success-
fully fabricate gemcitabine-loaded albumin nanospheres
(GEM-ANPs) with different sizes [15]. In this study,
human pancreatic carcinoma (PANC-1) was further ap-
plied to detect the antineoplastic effects of GEM-ANPs.
In particular, the in vivo antitumor activity of GEM-
ANPs was tested in a PANC-1-induced nude mice xeno-
graft model. Additionally, the drug distribution and toxic
side effects of GEM-ANPs were also investigated.
Methods
Materials
Gemcitabine (hydrochloride) was purchased from Hansen
Pharmaceutical Co., Ltd. (Jiangsu, China), and bovine
serum albumin (BSA, ≥98%, Mw = 68,000) was purchased
from Bo’ao Biological Technology Co., Ltd. (Shanghai,
China). PANC-1, an ATCC human pancreatic cancer cell
line, was purchased from the Shanghai Institute of
Biochemistry and Cell Biology (Shanghai, China). All other
solvents and chemicals were analytical grade.
Preparation of gemcitabine-loaded albumin nanospheres
GEM-ANPs, with a mean diameter of 110 nm (110-nm
GEM-ANPs) and 406 nm (406-nm GEM-ANPs), re-
spectively, were prepared using a modified desolvation-
cross-linking method according to our previous work
[15]. Briefly, 10 mL of 2% BSA aqueous solution was
mixed with 17 to 22 mg of gemcitabine at room
temperature. The pH value of the mixed solution was
adjusted to 8.0 to 9.0. An adequate amount of ethanol
was added dropwise at a rate of 1 mL/min under stir-
ring. Then the equivalent gemcitabine aqueous solution
(pH 8.5) was added into the mixed solution. After
stirring for 30 min, glutaraldehyde was added, and the
reaction system was allowed to cross-link under stirring.
The ethanol was removed by a rotary evaporator at
40°C (ZX-91, Institute of Organic Chemistry, Chinese
Academy of Science, Shanghai, China). The nanospheres
were centrifuged at 18,640×g for 20 min. Finally, the
precipitation was washed with pure water three times,
and the nanosphere powder could be obtained after
lyophilization treatment.In this study, 110-nm GEM-ANPs could be fabricated
at pH 9.0, with an albumin/ethanol volume ratio of
1:2.5, a glutaraldehyde/albumin acid molar ratio of 1:1,
and 6 h of cross-linking time. On the other hand,
406-nm GEM-ANPs could be fabricated at pH 8.0, with
an albumin/ethanol volume ratio of 1:4, a glutaralde-
hyde/albumin acid molar ratio of 3:1, and 12 h of cross-
linking time. The mean diameter, drug loading, drug
encapsulation efficiency, and zeta potential were 109.7 ±
2.2 nm and 405.6 ± 3.5 nm, 11.25% and 13.40%, 82.92%
and 92.56%, and −24.4 and −15.6 mV for 110-nm GEM-
ANPs and 406-nm GEM-ANPs, respectively. The blank
ANPs were prepared using the same procedure as that
for the drug-containing nanospheres but without the
addition of gemcitabine.
Antineoplastic activity of GEM-ANPs in vitro
Cell metabolic activity assay
PANC-1 cells were cultured in RPMI 1640 supple-
mented with 10% fetal calf serum, 50 U penicillin/mL,
and 50 μg streptomycin/mL in a humidified atmosphere
with 95% O2 and 5% CO2 at 37°C. Exponentially growing
cells were seeded into 96-well plates and preincubated
for 24 h. Then the medium was replaced with the fresh
RPMI 1640 medium containing 0.01 to 50 μg/mL of
gemcitabine or GEM-ANPs or ANPs. Samples were
sterilized by 60 Co radiations before exposure to cells.
Cell activity after 72 h of further culture was measured
by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide assay (MTT) with optical density at 490 nm
(OD490 nm) using a micro plate reader (EL×800,
BioTek, Winooski, VT, USA) (n = 5). A blank control
group without medication was used as control. The
inhibition rate was calculated as follows:
Inhibition rate ¼ ODc  ODtð Þ=ODc  100%
where ODc and ODt are the OD490 nm values of the
control group and the treatment group, respectively.
The half maximal inhibitory concentration (IC50) was
calculated with the Bliss method [16,17].
Cell cycle analysis by flow cytometry
After exposure to different samples for 72 h, PANC-1
cells were released by treatment with trypsin, washed
with phosphate buffered solution (0.01 M, pH 7.4), and
fixed in ice-cold 95% ethanol. After centrifugation at
252×g for 5 min, the cells were pretreated with 1 mL
Triton X-100 and centrifuged at 252×g for 5 min. A fur-
ther treatment with 1 mL RNase was performed at 37°C
for 10 min. Then the DNA of cells was stained with 1
mL propidium iodide. Cell cycle variation after different
treatment was analyzed with a FACS flow cytometer
(FACS Calibur, Becton-Dickinson, Franklin Lakes, NJ,
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Drug distribution and toxic side effect assessment in vivo
Animals
Male Sprague–Dawley (SD) rats, 4 to 5 weeks old,
(Shanghai SLAC Laboratory Animal Co., Ltd., Shanghai,
China) were housed in sterilized cages and fed with
autoclaved food and water ad libitum. Athymic nude
male mice, 6 to 8 weeks old, were purchased from
Shanghai SLAC Laboratory Animal Co., Ltd. and housed
in a specific pathogen-free animal facility. All animal
procedures were approved by the institutional animal
care committee, the Science and Technology Commis-
sion of Shanghai Municipality. All guidelines met the
ethical standards required by law and also complied with
the guidelines for the use of experimental animals in
China.
Drug distribution
A total of 30 clean laboratory SD rats, with an average
weight of 200 g, were randomly divided into three
groups as follows:
Group A: 110-nm GEM-ANPs
Group B: 406-nm GEM-ANPs
Group C: pure gemcitabine
Samples were sterilized by 60 Co radiations and dis-
persed into 1 mL saline before injection. After being
anesthetized with 10% chloral hydrate by intraperitoneal
injection (3.0 mL/kg), SD rats were injected with the
solution through the femoral vein. The amount of the
injection in the 110-nm GEM-ANP group, 406-nm
GEM-ANP group, and gemcitabine group was converted
from gemcitabine (90 mg/kg, n = 10). Six hours later,
the animals were killed. Tissues from the pancreas, liver,
spleen, heart, lung, and kidney were taken out and dir-
ectly kept in liquid nitrogen. When the gemcitabine con-
centration was analyzed, 0.2 g tissue was taken out and
homogenized with an adequate amount of physiological
saline. After centrifugation at 5,000×g for 5 min at 4°C,Table 1 Blood parameters of SD rats treated with the differen
Parameters Formula
110-nm GEM-ANPs 406-nm GEM-ANPs
Normal dose High dose Normal dose High d
WBC (109/L) 7.3 ± 1.1 5.3 ± 2.0 6.1 ± 1.2 5.1 ±
RBC (1012/L) 5.6 ± 1.8 6.2 ± 1.6 6.2 ± 2.1 6.1 ±
Hb (g/L) 130.0 ± 23.0 134.0 ± 20.0 141.0 ± 14.0 138.0 ±
ALT (U/L) 44.8 ± 14.0 52.5 ± 12.9 46.0 ± 11.3 54.3 ±
AST (U/L) 109.1 ± 22.1 128.0 ± 31.8 115.5 ± 26.0 113.1 ±
Cr (mM/L) 7.1 ± 2.4 8.7 ± 3.2 6.2 ± 1.5 7.8 ±
BUN (μM/L) 41.0 ± 15.1 45.5 ± 17.3 35.4 ± 16.0 40.9 ±0.2 mL of the supernatant was mixed with 0.1 mL
5-bromouracil and 1 mL methanol/acetonitrile (1:9, v/v)
by swirling. Then the mixed solution was kept static for
2 min and centrifuged at 5,000×g for 5 min at 4°C. The
supernatant was flushed with nitrogen gas and resolved
in the mobile phase, containing 125 μL of 0.05 mol/L
ammonium acetate buffer and methanol (pH 5.7, 90:10,
v/v). After centrifugation at 5,000×g for 5 min at 4°C,
the gemcitabine content in the supernatant was deter-
mined by high-performance liquid chromatography
(HPLC), with a Diamond C18 chromatographic column
(5 μm, ID 4.6 × 300 mm, Anoka, MN, USA) and at a
flow rate of 1 mL/min.
Toxic side effect assessment
Both the high-dose (200 mg/kg) and low-dose (100 mg/kg)
groups were constructed, as shown in Table 1. After
administration for 3 weeks, each blood sample was col-
lected from the arteriae femoralis. Different blood pa-
rameters, including white blood count (WBC), red blood
cell count (RBC), hemoglobin (Hb), alanine aminotrans-
ferase (ALT), aspartate aminotransferase (AST), creatin-
ine (Cr), and urea (BUN), were measured using a
biochemical autoanalyzer (Type 7170, Hitachi, Tokyo,
Japan). The samples obtained from healthy mice were
used as control.
Antitumor activity in vivo
Tumor induction and drug administration
Each male nude mice (n = 30) was injected subcutane-
ously in the back skin with 0.2 mL PANC-1 cell line
(1.0 × 108/mL). Those mice were randomly divided into
five groups (n = 6):
Group A: 110-nm GEM-ANPs
Group B: 406-nm GEM-ANPs
Group C: pure gemcitabine
Group D: blank ANPs
Group E: control (0.9% NS)
One week later, a tumor about 5 mm in diameter
could be observed in the mice. Then five groups of micet formulations for 3 weeks
tion (n = 6, p > 0.05)
Gemcitabine ANPs Control
ose Normal dose High dose High dose -
2.2 6.1 ± 1.3 4.8 ± 2.8 8.2 ± 2.2 7.3 ± 1.9
1.1 6.5 ± 2.9 6.0 ± 2.0 6.6 ± 2.9 6.4 ± 1.2
16.0 139.0 ± 20.0 132.0 ± 16.0 148.0 ± 23.0 143.0 ± 19.0
12.8 51.8 ± 15.3 60.2 ± 21.9 44.7 ± 11.5 48.8 ± 13.2
26.9 129.4 ± 28.1 136.3 ± 33.4 113.3 ± 28.4 109.5 ± 25.7
2.07 6.1 ± 1.9 7.4 ± 2.2 4.9 ± 1.5 6.1 ± 1.6
19.5 36.1 ± 18.2 45.0 ± 13.7 47.2 ± 16.2 41.3 ± 18.6
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gemcitabine or GEM-ANPs containing the equivalent
gemcitabine every 5 days, and a total of four treatments
was performed. Control mice received 200 μL of saline,
while blank mice were treated with unloaded ANPs.Antitumor activity assessment
Tumor size was measured with a vernier caliper at the
given intervals. Tumor volume (TV) was calculated with
the following formula:
TV ¼ 1 6= Þ  π  a  b2

where a and b were the long and short diameter of
tumor, respectively. Five weeks later, the animals were
killed and weighed. Tumors were stripped and weighed.
Moreover, the diameter and volume of tumors were also
measured. Tumor volume inhibition rate = (Differences
in mean tumor volume between the beginning and end of
treatment group) / (Differences in mean tumor volume
between the beginning and end of control group) × 100%;
Tumor weight inhibition rate = (Differences in mean
tumor weight between treatment group and control
group) / (Mean tumor weight of control group) × 100%.Histological analysis
The tumor tissues were carefully removed from each
animal, fixed with 10% formalin, dehydrated in alcohol,
and then embedded in paraffin. After sectioning and
hematoxylin and eosin staining, the samples were exam-
ined to analyze the histological changes of the tissues.Tumor proliferation and apoptosis analysis
The samples were stained by the method of EnVision
(enhance labeled polymer system). In the microscopy vi-
sion, the background was blue or purple, and the posi-
tive products were yellow or brown. Ten consecutive
cells under the ordinary optical microscope were ob-
served, and the number of positive cells in at least 1,000
cells was counted. Tumor proliferation index (PI) was
calculated as a percentage of Ki-67-positive cells.
Terminal transferase dUTP nick end labeling (TUNEL)
assay is a method used to detect DNA degradation in
apoptotic cells, and TUNEL kit was purchased from the
Boehringer Mannheim GmbH (Mannheim, Germany).
Brown particles in nucleus is determined to be the posi-
tive apoptotic cells. Ten consecutive cells were observed,
and the number of positive cells in at least 1,000 cells was
counted. The tumor apoptosis index (AI) was expressed
as a percentage of the TUNEL-positive cells in the tumor
cells.Statistical analysis
The number of independent replica was listed individu-
ally for each experiment. All data were expressed as
mean ± standard deviation. Statistical analysis was
performed with analysis of variance using SPSS 11.5
software, and p < 0.05 was considered to be statistically
significant.Results
Cytotoxicity of GEM-ANPs on PANC-1 cells in vitro
Figure 1 shows the inhibition rates of ANPs, gemcitabine,
110-nm GEM-ANPs, and 406-nm GEM-ANPs on the
metabolism of PANC-1 cells measured by the MTT
method, which is associated with the function of the
mitochondria. It can be seen that the inhibition rate of
ANPs reaches about 20% in 72 h, and the exposure time
and tested concentration of ANPs have no effect on cell
metabolism. Generally speaking, the inhibition effect of
gemcitabine, 110-nm GEM-ANPs, and 406-nm GEM-
ANPs on PANC-1 cells increases with the increase of
concentration and the prolongation of the exposure time.
However, 110-nm GEM-ANPs can only show a significant
inhibition after 48 h of exposure when the concentration
is over 10 μg/mL. With the prolongation of the exposure
time, the toxicity of 110-nm GEM-ANPs obviously en-
hances, and 0.01 μg/mL of sample could result in a 40.25
± 3.06% inhibition rate in 72 h. Moreover, the IC50 value
can be calculated to be 0.10 μg/mL. Additionally, both
gemcitabine and 406-nm GEM-ANPs exhibit a higher in-
hibition effect on PANC-1 cells in 48 h, but no significant
difference between both of them can be observed. After
78 h of exposure, the IC50 values of gemcitabine and 406-
nm GEM-ANPs reach 0.04 and 0.05 μg/mL, respectively.
Especially, 406-nm GEM-ANPs display a higher inhibition
rate than gemcitabine when the concentration reaches 50
μg/mL (p < 0.05).
The classification of cells into various phases of cell
cycle was measured by flow cytometry technique, and
the corresponding proliferation index and apoptosis
index were calculated, as shown in Table 2. The PI cell
cycle analysis reveals that cell proportion at the G0-G1
phase is significantly increased after exposure to
110-nm GEM-ANPs and 406-nm GEM-ANPs as com-
pared with the control (p < 0.05), but contrary to cells
at the S and G2-M phases. Both blank ANPs and
gemcitabine do not show significant difference com-
pared with the control at the proliferation index (p >
0.05). In addition, the AI cell cycle analysis reveals that
the apoptotic cells increase from 1.8 ± 0.7% in the
control group to 3.6 ± 1.5% in the 110-nm GEM-ANP
group, to 6.3 ± 1.2% in the 406-nm GEM-ANP


























































Figure 1 Inhibition rate. Gemcitabine concentration profile of 406-nm GEM-ANPs, 110-nm GEM-ANPs, gemcitabine, and ANPs on the human
pancreatic cancer cell line PANC-1 after exposure for 48 and 72 h in vitro.
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in vivo
Table 3 shows the gemcitabine content in different tis-
sues after injection of gemcitabine, 110-nm GEM-ANPs,
and 406-nm GEM-ANPs for 6 h, respectively, deter-
mined by HPLC. It can be seen that the gemcitabine
concentration in the 406-nm GEM-ANP group is signifi-
cantly increased in the liver, spleen, and pancreas (p <
0.05). It reaches values 5.4, 2.1, and 1.4 times higher
than those in the gemcitabine group, respectively. How-
ever, no significant difference among other organs could
be observed (p > 0.05). Table 1 showed the different
blood parameters in order to assess the toxic side effects
of GEM-ANPs. With respect to those observed forTable 2 The proliferation and apoptosis of the pancreatic can
Group G0-G1 (%) S (%)
110-nm GEM-ANPs 45.8 43.6




After exposure to 0.1 μg/mL of different samples for 72 h, analyzed by flow cytome
and ANP group, p < 0.05.untreated healthy mice, both the low- and high-dose
groups of 110-nm GEM-ANPs and 406-nm GEM-ANPs
elicit no significant variation of rat blood parameters
after 3 weeks of administration (p > 0.05).
After administration of 110-nm GEM-ANPs, 406-nm
GEM-ANPs, and gemcitabine for 6 h, respectively
(n = 30). *Significant difference compared with gemci-
tabine group, p < 0.05.
Antitumor activity of GEM-ANPs in vivo
After 5 weeks of treatment, the tumor growth curve was
drawn using the checkpoint data every 5 days, as shown
in Figure 2. The control group exhibits a gradual in-
crease trend in the tumor volume, ranging from 149.4 ±cer cell line
G2-M (%) PI (%) AI (%)
10.6 54.2 ± 8.7* 3.6 ± 1.5*
7.5 56.0 ± 8.1* 6.3 ± 1.2*
18.2 64.67 ± 6.4 3.74 ± 0.4*
18.8 74.11 ± 3.6 2.56 ± 0.1
17.9 71.46 ± 4.8 1.78 ± 0.7
try technique (n = 5). *Significant difference compared with both control group
Table 3 Gemcitabine contents (μg/g) in different organs
of SD rats
Organ 110-nm GEM-ANPs 406-nm GEM-ANPs Gemcitabine
Heart 104.9 ± 11.1 113.3 ± 18.9 117.1 ± 15.9
Liver 2.7 ± 2.5* 43.6 ± 13.4* 8.0 ± 7.2
Spleen 2.8 ± 1.9* 35.3 ± 7.8* 16.9 ± 5.1
Pancreas 101.6 ± 13.8 155.6 ± 11.8* 112.6 ± 5.8
Lung 8.0 ± 3.7 8.3 ± 3.6 13.9 ± 7.3
Muscle 92.8 ± 15.1 81.6 ± 11.3 84.9 ± 5.4
Kidney 105.8 ± 15.6 92.1 ± 12.9 99.7 ± 7.7
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tumor volume in the mice treated with 406-nm GEM-
ANPs decreases gradually and varies from 148.19 ±
10.35 mm3 to 23.7 ± 20.1 mm3. Moreover, the inhibition
rate of tumor volume reaches 168.8% (Table 4). Besides,
both gemcitabine and 110-nm GEM-ANPs can also in-
hibit the increase of tumor volume, and the inhibition
rate reaches 109.9% and 75.1%, respectively (Table 4).
However, the tumor volume shows an increase trend
after discontinuation of 110-nm GEM-ANPs or gemci-
tabine (Figure 2). The weight of the collected tumor
masses confirms these findings. In fact, masses of 0.175,
0.090, and 0.166 g were observed in the case of 110-nm
GEM-ANPs, 406-nm GEM-ANPs, and gemcitabine
treatment, respectively, while control animals and ANPs
show tumoral masses of 0.291 and 0.245 g, respectively
(Table 4 and Figure 3). Besides, the reduction in tumor
blood supply could be seen in the 406-nm GEM-ANP
group, while they are relatively rich in the gemcitabine

























Figure 2 Tumor growth curves in a PANC-1-induced nude mice xenog
point of administration.Histological analysis of tumor masses after various
treatments for 5 weeks was performed by H & E stain-
ing; the proliferation and apoptosis of tumor cells were
also determined by immunohistochemical assay on
Ki-67 protein and TUNEL assay, as shown in Figure 4.
H & E staining confirms that the tumor cell proliferation
and division are more active in the control group than
in other groups. In addition, Ki-67 protein immunohis-
tochemical assay indicates that the proliferation index
of tumor cells in 110-nm GEM-ANP (36.4 ± 8.1%),
406-nm GEM-ANP (25.6 ± 5.7%), and gemcitabine (38.4
± 9.4%) groups are lower than that in the blank ANP
and control group, with significant difference (p < 0.05).
At the same time, TUNEL assay reveals that the apop-
totic index of tumor cells in the 406-nm GEM-ANP
(38.5 ± 17.2%) group is significantly higher than that in
the 110-nm GEM-ANP (33.6 ± 11.2) and gemcitabine
(32.2 ± 9.7%) groups (Figure 4).
Discussion
As one of the most lethal cancers, pancreatic cancer is
still a frequently occurring disease and remains a
therapeutic challenge to humans [18,19]. Although
gemcitabine is a currently and widely used drug in the
therapy of pancreatic cancer, various approaches, such
as drug delivery system, have to be tried to prolong the
plasma half-life of gemcitabine and enhance its bioavail-
ability [20,21]. As the typical examples, liposome and
carbon nanotube have been a success in delivering can-
cer drugs for pancreatic cancer treatment in recent
animal and preclinical trials [19,22]. Nowadays, a novel
carrier system allowing for lower toxic side effects and
higher tumor-targeting efficiencies is emphasized, while




raft model after different treatments. Red arrows indicate the time
Table 4 The inhibition rate of GEM-ANPs on tumor growth in the PANC-1-induced nude mice tumor model











5 days 35 days
110-nm GEM-ANPs 144.9 ± 12.2 187.3 ± 32.4 42.4 75.1 0.175 39.9
406-nm GEM-ANPs 148.2 ± 10.4 31.0 ± 16.1 −117.2 168.8* 0.090* 69.1*
Gemcitabine 149.64 ± 20.35 132.80 ± 28.2 −16.8 109.9 0.166 43.0
ANPs 147.6 ± 22.7 250.6 ± 27.2 103.0 39.6 0.245 15.81
Control 149.4 ± 18.2 319.9 ± 30.3 170.5 0.0 0.291 0.0
n = 30. aInhibition rate of tumor volume = (Differences in mean tumor volume between the beginning and end of treatment group) / (differences in mean tumor
volume between the begin and end of control group) × 100%. bThe tumor weight was measured at 35 days after administration. cInhibition rate of tumor weight
= (Differences in mean tumor weight between treatment group and control group) / (Mean tumor weight of control group) × 100%. *Significant difference
compared with gemcitabine group, p < 0.05.
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troduced to act as a drug carrier for gemcitabine loading
[15]. We found that GEM-ANPs could result in a
sustained release and improved antitumor activity
in vitro of gemcitabine. Here, we further exposed human
pancreatic carcinoma (PANC-1) to GEM-ANPs and
studied cell responses in vitro by cell viability analysis
and flow cytometry technique. The loading of
gemcitabine on albumin did not reduce the inhibition
effect of gemcitabine on PANC-1 metabolism. Moreover,
GEM-ANPs with bigger size could even enhance the
killing efficacy of gemcitabine in pancreatic carcinoma
(Figure 1). GEM-ANPs showed their cell cycle inhibitory
property, in the order of 406-nm GEM-ANPs > 110-nm
GEM-ANPs > gemcitabine. The higher antiproliferative
activity of 406-nm GEM-ANPs could be attributed
to the S phase arrest during cell cycle progression
(Table 2).
Besides the shorter half-life, the toxic side effects, like
increased liver enzymes and leukopenia, have also lim-
ited the applications of gemcitabine [24]. Therefore, the
blood parameters of rats treated with GEM-ANPs were
investigated to assess the reduction effect of albumin
loading on gemcitabine toxic side effects. Since the blank
nanoparticles could interfere with the growth of cells
in vitro, the US Pharmacopoeia limits cell inhibition as
no more than 50% for safety [25]. The present studyFigure 3 Neoplastic mass comparison among different treatment gro
model following their scarification at the end of the experiments. A 110-nmrevealed that no significant difference between the ANP
treatment group and control group was observed in
WBC, RBC, and other parameters of hepatonephric
functions, suggesting a satisfactory biocompatibility
(Table 1). What was more important was that the high-
dose treatment with GEM-ANPs, especially 406-nm
GEM-ANPs, could reduce the side effects of gemcitabine
(Table 1). In fact, gemcitabine concentration and treat-
ment period were insufficient to induce a relevant blood
toxicity in the present study [26]. Our results also dem-
onstrated that gemcitabine loading on 406-nm GEM-
ANPs significantly increased the gemcitabine content in
the pancreas, liver, and spleen of SD rats compared with
the gemcitabine treatment group, but contrary to 110-
nm GEM-ANPs (p < 0.05) (Table 3). It is well known
that nanospheres are easily taken up by cells of the
mononuclear phagocyte system, primarily those located
in the reticuloendothelial system-rich organs, such as
the liver and spleen [27]. Furthermore, phagocytosis will
gradually increase as the size is more than 200 nm [28].
Consequently, it might be one of the reasonable mecha-
nisms for the targeting effect of 406-nm GEM-ANPs
in vivo [29]. That was to say, 406-nm GEM-ANPs would
enhance the curative effect of gemcitabine in pancreatic
cancer. Particularly, literatures have reported that the
microvascular permeability of most normal tissues was
generally less than 50 nm, but ten times higher in tumorups. After being excised from the PANC-1-induced nude mice tumor
GEM-ANPs, B 406-nm- GEM-ANPs, C gemcitabine, D ANPs, and E control.
Figure 4 Histological analysis of neoplastic masses by H & E staining, Ki-67 protein, and TUNEL assay after being excised from the
PANC-1-induced nude mice tumor model following their scarification at the end of the experiments. A 110nm-GEM-ANPs, B 406-nm-
GEM-ANPs, C gemcitabine, D ANPs and E control.
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Hobbs et al. found that the microvascular permeability
of rat hepatoma, fibrosarcoma, and human colon cancer
animal model reach 380 to 550, 550 to 780 and 380 to
550 nm, respectively [30]. Yuan et al. also found that the
maximum diameter of microvascular permeability in
human colon cancer is between 400 and 600 nm [31]. In
addition, Desai [32] and Cortes and Saura [33] found
that albumin nanoparticles could increase albumin re-
ceptor, 60-kDa glycoprotein (gp60)-mediated transcy-
tosis, through microvessel endothelial cells in angiogenic
tumor vasculature and targets the albumin-binding pro-
tein SPARC, which subsequently increased intratumoral
accumulation. Therefore, a relatively high antitumor ac-
tivity of 406-nm GEM-ANPs could be expected due to
the passive targeting by EPR effect and gp60-mediated
transcytosis [8-10,23,32,33]. Here, the antitumor effects
of GEM-ANPs were assessed in vivo using the implanted
tumor model of nude mice. We found that the
antitumor effect of 406-nm GEM-ANPs was greatest
(Figures 2 and 3), with 168.8% inhibitory rate compared
to the control. Finally, the slow release of gemcitabine
from 406-nm GEM-ANPs could also prolong the drug
action, and it might be another possible reason for the
higher antitumor activity of GEM-ANPs.
Conclusions
GEM-ANPs with different sizes had been prepared by
the modified desolvation-cross-linking method. Their
biodistribution, toxic side effects, and in vitro andin vivo antitumor activity were studied. The following con-
clusions can be drawn from the study described here:
(1)GEM-ANPs showed significant inhibition effects on
human pancreatic carcinoma, but the inhibition rate
was size dependent.
(2)The suitable size of 406-nm GEM-ANPs resulted in
a higher gemcitabine content in the pancreas, liver,
and spleen of SD rats and a lower blood toxicity
through a passive targeting model.
(3)A more efficient antitumor activity was demonstrated
in a pancreatic cancer xenograft model for 406-nm
GEM-ANPs with respect to that of free gemcitabine.
Therefore, the orthotopic model for pancreatic cancer
remains to be examined in our future work.
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